TNF Competitors

Delisted . USA . 
Stock . TNF Pharmaceuticals
TNFADelisted Stock   5.20  0.56  9.72%   
TNF Pharmaceuticals competes with CervoMed, COSCIENS Biopharma, Tvardi Therapeutics, and Biora Therapeutics; as well as few others. The company conducts business under Pharmaceuticals sector and is part of Health Care industry. Analyzing TNF Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of TNF Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.

TNF Pharmaceuticals vs Biora Therapeutics Correlation

Moving together with TNF Stock

  0.84ORGN Origin MaterialsPairCorr

Moving against TNF Stock

  0.87AA Alcoa Corp Downward RallyPairCorr
  0.86XOM Exxon Mobil Corp Aggressive PushPairCorr
  0.86BA BoeingPairCorr
  0.81JNJ Johnson JohnsonPairCorr
  0.8MRK Merck Company Aggressive PushPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
5.205.205.20
Details
Intrinsic
Valuation
LowRealHigh
4.944.945.72
Details
Naive
Forecast
LowNextHigh
5.925.925.92
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.987.8214.67
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as TNF Pharmaceuticals. Your research has to be compared to or analyzed against TNF Pharmaceuticals' peers to derive any actionable benefits. When done correctly, TNF Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in TNF Pharmaceuticals.

TNF Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between TNF Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of TNF and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of TNF Pharmaceuticals does not affect the price movement of the other competitor.

High positive correlations

OMGA
+ 0.72
CSCI
OMGA
+ 0.6
CHRO
TSBX
+ 0.46
CYCC
CSCI
+ 0.36
CHRO
TVRD
+ 0.23
CSCI
TVRD
+ 0.11
CYCC
  

High negative correlations

CYCC
- 0.64
CHRO
OMGA
- 0.56
CYCC
OMGA
- 0.48
TSBX
TSBX
- 0.47
CHRO
TSBX
- 0.29
CSCI
CSCI
- 0.27
CYCC

Risk-Adjusted Indicators

There is a big difference between TNF Stock performing well and TNF Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze TNF Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
CHRO  5.31  0.28  0.05  0.20  5.79 
(7.41)
 10.27 
(10.69)
 68.90 
CRVO  3.15 (0.53) 0.00  1.10  0.00 
 0.00 
 6.31 
(7.29)
 19.42 
APGN  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
CYCC  13.81  3.48  0.30 (0.66) 9.13 
(21.63)
 22.50 
(17.15)
 306.00 
CSCI  6.75  0.10  0.00  6.52  11.44 
(8.07)
 27.11 
(28.04)
 94.83 
TVRD  2.63 (0.29) 0.00 (0.23) 0.00 
 0.00 
 5.59 
(5.80)
 17.33 
TSBX  2.57  0.15  0.03  0.27  3.05 
(4.24)
 6.06 
(6.06)
 21.24 
OMGA  22.28  1.75  0.07  2.09  23.86 
(31.18)
 72.73 
(52.09)
 155.58 
BIOR  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 

TNF Pharmaceuticals Competitive Analysis

The better you understand TNF Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, TNF Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across TNF Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
TNFA CHRO CRVO CYCC CSCI TVRD TSBX OMGA BIOR
 9.72 
 5.20 
TNF
 8.20 
 16.50 
Chromocell
 3.31 
 4.67 
CervoMed
 5.77 
 6.37 
Cyclacel
 2.38 
 2.05 
COSCIENS
 2.28 
 3.86 
Tvardi
 0.00 
 0.36 
Turnstone
 21.25 
 0.05 
Omega
 0.00 
 0.22 
Biora
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Slightly risky
Very steady
Abnormally volatile
Relatively risky
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Hazard
Hazard
Small
Hazard
Moderate
Risky
Hazard
Hazard
Risky
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Under Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Strong Buy
Not Available
Not Available
Strong Buy
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Not Rated
Strong Sell
Not Rated
Strong Sell
Strong Sell
Not Rated
Not Rated
Strong Sell
Current Ratio
N/A
N/A
N/A
6.38
N/A
N/A
N/A
13.46
1.69
Net Asset
21.42 M
1.37 M
43.08 M
4.09 M
35.07 M
43.83 M
40.14 M
204.37 M
31.21 M
Profit Margin
N/A
N/A
N/A
N/A
-2.0
N/A
N/A
N/A
N/A
EBITDA
(23.36 M)
(7.57 M)
(18.23 M)
(12 M)
(13.49 M)
(62.6 M)
(68.97 M)
(93.49 M)
(114.05 M)
Current Valuation
5.9 M
91.42 M
17.77 M
10.9 M
1.31 M
221.23 M
(8.06 M)
100.44 M
38.44 M
Price To Book
1.26
4.11
1.72
4.18
1.17
N/A
0.56
0.23
N/A
Operating Margin
N/A
N/A
-24.94
N/A
-0.86
N/A
N/A
-6.29
N/A
Retained Earnings
(129.14 M)
(21.47 M)
(70.73 M)
(439.49 M)
(12.11 M)
(755.61 M)
(247.59 M)
(334.63 M)
(950.96 M)
Current Asset
N/A
317 K
N/A
24.57 M
N/A
N/A
N/A
N/A
667 K
Beta
2.28
N/A
-6.23
0.16
1.85
N/A
1.37
1.64
1.28
Number Of Employees
6
4
15
10
40
12
14
93
58
Shares Outstanding
1.85 M
6.6 M
9.25 M
2.24 M
3.18 M
9.36 M
23.14 M
55.37 M
4.52 M
Cash Flow From Operations
(8.98 M)
(5.79 M)
(16.53 M)
(7.99 M)
(14.57 M)
(60.92 M)
(67.44 M)
(91.51 M)
(48.5 M)
Annual Yield
N/A
N/A
N/A
0.49
N/A
N/A
N/A
N/A
N/A
Total Debt
10.58 K
2.19 M
3.88 M
6.27 M
2.31 M
44.45 M
1.19 M
128.43 M
47.43 M
Return On Equity
-1.15
N/A
-0.71
-2.77
-1.13
N/A
-1.27
-1.67
N/A
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.24
-1.89
-0.43
-1.03
-0.17
N/A
-0.58
-0.25
-1.25
Number Of Shares Shorted
5.72 M
76.91 K
193.62 K
96.28 K
9.91 K
547.71 K
281.36 K
5.21 M
258.12 K
Book Value Per Share
17.47
-6.78
2.81
2.29
2.24
-5.29
0.64
0.21
-36.43
Current Liabilities
N/A
166 K
N/A
5.75 M
N/A
N/A
N/A
N/A
3.01 M
Total Asset
21.42 M
1.37 M
43.08 M
4.09 M
35.07 M
43.83 M
40.14 M
204.37 M
31.21 M
Short Ratio
0.07
0.88
3.55
0.01
1.67
0.26
1.27
6.97
2.37
Target Price
N/A
8.5
22.43
1.0
N/A
56.2
1.0
11.5
34.0
Debt To Equity
N/A
N/A
N/A
0.003
N/A
N/A
N/A
0.15
N/A
Shares Owned By Institutions
0.29
13.6
23.84
0.79
8.93
2.76
51.49
87.75
36.0
Market Capitalization
6.48 M
8.9 M
44.69 M
15.16 M
8.64 M
242.26 M
8.21 M
7.9 M
1.86 M
Price To Earning
N/A
N/A
N/A
-0.4
N/A
N/A
N/A
N/A
N/A
Price To Sales
N/A
N/A
7.26
1515.79
0.92
N/A
2.13
0.98
1.49
Net Income
(23.36 M)
(7.96 M)
(16.29 M)
(11.21 M)
(15.31 M)
(70.87 M)
(70.84 M)
(97.43 M)
(124.11 M)
Earnings Per Share
-202.0
-12.0
-2.9
7123.5
-6.54
-2.25
-2.04
-1.32
0.36
Shares Owned By Insiders
0.009
53.88
32.16
80.14
1.48
27.53
7.69
1.6
0.1
Revenue
N/A
N/A
9.74 M
43 K
13.78 M
7.14 M
N/A
3.09 M
4 K
Working Capital
2.71 M
(2.71 M)
39.2 M
(2.59 M)
16.76 M
22.88 M
26.02 M
63.08 M
(43.9 M)
Cash And Equivalents
N/A
N/A
N/A
29.08 M
N/A
N/A
N/A
173.66 M
37.06 M
Cash Per Share
N/A
N/A
N/A
2.32
N/A
N/A
N/A
3.63
0.19
Gross Profit
N/A
272.31 K
(16.91 M)
10 K
4.42 M
N/A
(55.63 M)
(34.5 M)
1.25 M
Day Typical Price
6.11
15.93
4.72
6.48
2.07
4.03
0.36
0.0448
0.22
Accumulation Distribution
0.53
0.22
2853.58
0.13
0.0238
17117.98
N/A
0.28
N/A
Market Facilitation Index
4.74
3.77
0.0
0.88
0.05
0.0
N/A
0.014
N/A
Daily Balance Of Power
(0.12)
0.3316
(0.67)
(0.44)
(1.00)
(0.14)
0.0
0.6071
0.0
Period Momentum Indicator
(0.56)
1.25
(0.16)
(0.39)
(0.05)
(0.09)
N/A
0.0085
N/A
Rate Of Daily Change
0.9
1.08
0.97
0.94
0.98
0.98
1.0
1.21
1.0
Day Median Price
6.57
15.65
4.74
6.54
2.08
4.12
0.36
0.043
0.22
Price Action Indicator
(1.65)
1.48
(0.15)
(0.36)
(0.05)
(0.30)
N/A
0.0098
N/A
Coefficient Of Variation
(1,970)
2216.27
(752.12)
1117.29
12213.73
(1,521)
1864.69
1837.69
N/A
Mean Deviation
8.7
5.31
3.15
13.81
6.75
2.63
2.57
22.28
N/A
Jensen Alpha
(0.77)
0.2787
(0.53)
3.48
0.104
(0.29)
0.152
1.75
N/A
Total Risk Alpha
(1.65)
(0.26)
(0.87)
0.5446
(0.94)
(0.49)
(0.09)
(0.66)
N/A
Sortino Ratio
N/A
0.0533
N/A
0.3008
0.0037
N/A
0.0267
0.0672
N/A
Downside Variance
N/A
37.71
N/A
110.31
186.29
N/A
26.08
669.27
N/A
Standard Deviation
13.16
8.68
4.14
36.02
14.03
3.45
3.74
33.11
N/A
Kurtosis
4.59
12.37
0.0455
49.71
7.23
0.7451
1.62
2.08
N/A
Potential Upside
17.75
10.27
6.31
22.5
27.11
5.59
6.06
72.73
N/A
Treynor Ratio
(0.40)
0.2022
1.1
(0.66)
6.52
(0.23)
0.2685
2.09
N/A
Maximum Drawdown
79.44
68.9
19.42
306.0
94.83
17.33
21.24
155.58
N/A
Variance
173.1
75.33
17.1
1297.36
196.96
11.89
14.0
1096.57
N/A
Market Risk Adjusted Performance
(0.39)
0.2122
1.11
(0.65)
6.53
(0.22)
0.2785
2.1
N/A
Risk Adjusted Performance
(0.03)
0.0423
(0.09)
0.0756
0.0155
(0.04)
0.0475
0.0498
N/A
Skewness
1.32
2.35
(0.07)
6.65
1.37
0.4624
0.1454
0.9848
N/A
Semi Deviation
N/A
5.79
N/A
9.13
11.44
N/A
3.05
23.86
N/A
Information Ratio
(0.06)
0.0377
(0.15)
0.0877
0.0036
(0.08)
0.0364
0.0525
N/A
Value At Risk
(20.86)
(10.69)
(7.29)
(17.15)
(28.04)
(5.80)
(6.06)
(52.09)
N/A
Expected Short fall
N/A
(7.41)
N/A
(21.63)
(8.07)
N/A
(4.24)
(31.18)
N/A
Downside Deviation
N/A
6.14
N/A
10.5
13.65
N/A
5.11
25.87
N/A
Semi Variance
N/A
33.54
N/A
83.4
130.79
N/A
9.28
569.52
N/A

TNF Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of TNF Pharmaceuticals Competition

TNF Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by TNF Pharmaceuticals in relation to its competition. TNF Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of TNF Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact TNF Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to TNF Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your TNF Pharmaceuticals position

In addition to having TNF Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Data Storage Thematic Idea Now

Data Storage
Data Storage Theme
Companies making data storages or providing data storage services. The Data Storage theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Data Storage Theme or any other thematic opportunities.
View All  Next Launch
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.
You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Other Consideration for investing in TNF Stock

If you are still planning to invest in TNF Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the TNF Pharmaceuticals' history and understand the potential risks before investing.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Stocks Directory
Find actively traded stocks across global markets
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY